RaQualia Pharma (Japan)

Recent papers from RaQualia Pharma (Japan)

1. An Orally Available Derivative of a Specific CK2 Inhibitor for Regulating Circadian Rhythms and Acute Myeloid LeukemiaPrecision Chemistry · 2026
2. AK1780, a selective P2X7 receptor antagonist with high central nervous system penetration, exhibits analgesic effect in rat neuropathic pain modelJournal of Pain · 2025
3. Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton PumpJournal of Medicinal Chemistry · 2022
4. Corticotropin releasing hormone receptor 2 antagonist, RQ-00490721, for the prevention of pressure overload-induced cardiac dysfunctionBiomedicine & Pharmacotherapy · 2021
5. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and MotilityJournal of Pharmacology and Experimental Therapeutics · 2017
6. Functional role of the transient receptor potential melastatin 8 ( TRPM 8) ion channel in the urinary bladder assessed by conscious cystometry and ex vivo measurements of single‐unit mechanosensitive bladder afferent activities in the ratBJU International · 2015
7. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like propertiesBreast Cancer Research and Treatment · 2013
8. Changes in the Function and Expression of T-Type and N-Type Calcium Channels in the Rat Bladder after Bladder Outlet ObstructionThe Journal of Urology · 2013
9. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE₂-mediated immunosuppression and inhibits breast cancer metastasisOncoImmunology · 2013